Dantari
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $47M
Overview
Developing a targeted drug delivery platform to create safer and more effective cancer therapies.
Oncology
Technology Platform
A proprietary targeted drug delivery platform designed to create high-payload antibody-drug conjugates (ADCs) with optimized stability and tumor-selective release.
Funding History
1Total raised:$47M
PIPE$47M
Opportunities
Potential to expand its platform beyond ADCs to deliver a range of therapeutic modalities, including radionuclides and immune modulators.
Risk Factors
High technical risk associated with novel delivery technologies and intense competition from well-funded ADC developers.
Competitive Landscape
Competes in the crowded ADC field against platforms from companies like Seagen (Pfizer), ImmunoGen, and Daiichi Sankyo, requiring clear differentiation in safety or efficacy.